



**COPY RECEIVED**  
SEP 25 2003  
TECH CENTER 1000/2900

5218.39B/KDS:vp  
January 21, 2002

Commissioner for Patents  
Washington, DC 20231

Sir: Kindly acknowledge receipt of the accompanying by placing your  
receiving date stamp hereon and mailing:  
Re: Anagnostou, et al.; S/N 09/525,797; Filed 3/15/00

IDS (W/21 REF.)



Respectfully,  
**MYERS BIGEL SIBLEY & SAJOVEC, P.A.**  
Attorneys for Applicant

Attorney's Docket No. 5218.358

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou, et al.  
Serial No. 09/525,797  
Filed: 15 March 2000  
For: METHOD OF TREATING ENDOTHELIAL INJURY

January 21, 2002


Commissioner for Patents  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on form PTO-1449. Items 1-21 listed on the PTO-1449 were cited in parent application Serial No. 08/712,358, filed 11 September 1996. Since the benefit of this application is claimed under 35 U.S.C. §120, no copies need to be furnished in accordance with 37 C.F.R. §1.98(d); however, copies will be furnished on request. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.97 and Section 609 of the MPEP.

Respectfully submitted,

  
Kenneth D. Sibley  
Registration No. 31,665




20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on January 21, 2002.

  
Vickie Diane Prior

Date of Signature: January 21, 2002

RECEIVED  
SEP 25 2003  
TECH CENTER 1600/2900



Attorney's Docket No. 5218-39B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al.

Serial No.: 09/525,797

Filed: March 15, 2000

For: *METHOD OF TREATING ENDOTHELIAL INJURY*

Confirmation No. 9917

Group Art Unit: 1642

Examiner: Susan Ungar

September 16, 2003

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED  
SEP 25 2003  
TECH CENTER 1600/2800

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Attached is a list of documents on Form PTO-1449, along with a copy of each listed document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP.

This Supplemental Information Disclosure Statement and Form PTO-1449 are submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first Office Action after the filing of a Request for Continued Examination. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Shawna Cannon Lemon

Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.

P. O. Box 37428, Raleigh, NC 27627

Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Customer No. 20792

**Certificate of Mailing under 37 CFR § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 16, 2003.

Susan E. Freedman

Date of Signature: September 16, 2003

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1



Complete if Known

Application Number	09/525,797
Filing Date	15 March 2000
First Named Inventor	Athanasius A. Anagnostou
Group Art Unit	1642
Examiner Name	S. Ungar
Attorney Docket Number	5218.39B

RECEIVED  
SEP 25 2003  
TECH CENTER 1600/2800

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	4,745,099		Akamatsu et al.	5/17/88	
	2	5,635,160		Stutts, et al.	3/6/97	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)			

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	3	Anagnostou et al., <i>Erythropoietin Has a Mitogenic and Positive Chemotactic Effect on Endothelial Cells</i> , <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 5978-5982 (1990)	
	4	Cao, et al., <i>gro-<math>\alpha</math>, a C-X-C-Chemokine Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice</i> , <i>J. Exp. Med.</i> , Vol. 182, 2069 (1995)	
	5	Carlini et al., <i>Effect of Recombinant Human Erythropoietin (rHuEPO) on Apoptosis in Endothelial Cells</i> , <i>J. Amer. Society Nephrology</i> , Vol. 7, No. 9, pp. 1559; Abstract A1548 (1996)	
	6	Carlini, et al., <i>Recombinant Human Erythropoietin Stimulates Angiogenesis</i> , <i>Kidney International</i> , Vol. 47, pp. 740-745 (1995)	
	7	Cazzola, M., <i>Erythropoietin: biology and clinical applications</i> , <i>Trends in Experimental and Clinical Medicine</i> , Vol. 3, pp. 344-361 (1993)	
	8	Hand, et al., <i>Erythropoietin Enhances Vascular Responsiveness to Norepinephrine in Renal Failure</i> , <i>Kidney International</i> , Vol. 48, pp. 806-813 (1995)	
	9	International Search Report for PCT/US97/15966	
	10	Kumar, et al., <i>Basic Pathology</i> , W. B. Saunders Company, Philadelphia, pg. 194 (1992)	
	11	Kuriyama et al., <i>Evidence for Amelioration of Endothelial Cell Dysfunction by Erythropoietin Therapy in Predialysis Patients</i> , <i>Am. J. Hyperten.</i> , Vol. 9, No. 5, pp. 426-431 (1996)	
	12	Kuwata, et al., <i>Treatment of Metastatic Liver Tumors by Intermittent Repetitive Injection of an Angiogenesis Inhibitor Using an Implantable Port System in a Rabbit Model</i> , <i>Kobe J. Med. Sci.</i> , Vol. 43, No. 2, pp. 83-98 (1997)	
	13	Livnah, et al., <i>Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å</i> , <i>Science</i> , Vol. 273, pp. 464-471 (1996)	
	14	Maier, et al., <i>In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNF-470) and the anti-endothelial antibody TEC-11</i> , <i>Anti-Cancer Drugs</i> , Vol. 8, pp. 238 (1997)	
	15	Markham, et al., <i>Epoetin Alfa, A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications</i> , <i>Drugs</i> , Vol. 49, No. 2, pp. 232-254 (1995)	
	16	Nagai, et al., <i>Effects of rHuEPO on Cellular Proliferation and Endothelin-1 Production in Cultured Endothelial Cells</i> , <i>Nephrol Dial Transplant</i> , Vol. 10, pp. 1814-1819 (1995)	
	17	Pluda, J.M., <i>Tumor-Associated Angiogenesis: Mechanisms, Clinical Implications, and Therapeutic Strategies</i> , <i>Seminars in Oncology</i> , Vol. 24, pp. 203 (1997)	
	18	Takano, et al., <i>A Diaminoanthraquinone Inhibitor of Angiogenesis</i> , <i>J. Pharmacol. Exp. Ther.</i> , Vol. 271, pp. 1027 (1994)	
	19	Wrighton, et al., <i>Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin</i> , <i>Science</i> , Vol. 273, pp. 458-463 (1996)	
	20	Yamaji et al., <i>Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA</i> , <i>European J. Biochem.</i> , Vol. 239, pp. 494-500 (1996)	
	21	Yamaji, et al., <i>Brain Capillary Endothelial Cells Express Two Forms of Erythropoietin Receptor mRNA</i> , <i>Eur. J. Biochem.</i> , Vol. 239, pp. 494 (1996)	

Examiner Signature

/Karen A. Canella, Ph.D./

Date Considered

08/18/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

SEP 22 2003

**Complete if Known**

Application Number	09/525,797
Filing Date	03/15/2000
First Named Inventor	Athanasius A. Anagnostou
Group Art Unit	1642
Examiner Name	Susan Ungar
Attorney Docket Number	5218-39B

### U.S. PATENTS AND PATENT PUBLICATIONS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner Signature**

/Karen A. Canella, Ph.D./

Date Considered

08/18/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/